Sign up Australia
Proactive Investors - Run By Investors For Investors

Neuren Pharmaceuticals granted ASX trading halt pending trial update

The halt will remain in place until Wednesday 22nd March 2017.
no_picture_pai.jpg
Neuren to update on trial

Neuren Pharmaceuticals (ASX:NEU) has been granted a trading halt by the ASX, with its shares placed in pre-open.

Neuren requested the halt pending details regarding Neuren’s Phase 2 clinical trial of trofinetide in Rett syndrome.

The halt will remain in place until the opening of trade on Wednesday 22nd March 2017, or earlier if an announcement is made to the market.



Register here to be notified of future NEU Company articles
View full NEU profile

Neuren Pharmaceuticals Timeline

Related Articles

Netscientific has its thumbs in a few clinical pies
April 01 2017
The firm commercialises intellectual property (IP) through developing early and mid-stage healthcare firms
cancer cells
January 25 2017
The US-based, London-listed healthcare group topped expectations with its latest results and analysts are tipping it for more success this year
hepatitisC.jpg
March 28 2017
Regulatory sign-off will fire the starting pistol on the commercial launch in Europe

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use